Search engines still steer Europeans toward illegal medicine sellers
Online pharmacy access is now part of everyday care, but the path from search box to checkout can lead patients toward illegal online medicine vendors selling substandard or falsified products. A pan-European analysis across 30 countries shows that legitimate online pharmacies dominated search engine results overall, yet the exposure to illegal sellers remained substantial enough to matter for patient safety, regulation, and search governance.
Investigators scraped the top 50 Google results in each country for six tracer active pharmaceutical ingredients spanning three categories: controlled substances, prescription-only medicines, and over-the-counter products. Across 9,000 search engine results pages, 3,839 links led to medicine-selling websites. Of those, 63.7% were legitimate online pharmacies and 36.3% were illegal online medicine vendors. The basic message is blunt: legal sellers were more visible, but illegal sellers were far from rare.
Controlled substances generated the heaviest illegal exposure
The sharpest signal came from drugs with tighter regulatory control. Illegal vendor prevalence rose from 1.4% for paracetamol to 5.5% for ibuprofen, 10.2% for omeprazole, 55.1% for amoxicillin, 76.2% for alprazolam, and 77.5% for clonazepam. Those gradients are not random noise. They track the commercial logic of illicit markets, where high-demand prescription medicines and psychoactive agents carry the greatest incentive for bypassing standard pharmacy controls.
The highest-risk products in this analysis were benzodiazepines. Alprazolam and clonazepam search queries were dominated by illegal vendors, reflecting the combination of dependence potential, consumer demand, and the temptation to obtain these medicines without a prescription. In practical terms, search results can become an unfiltered triage system for self-medication, with patients and caregivers encountering illegal suppliers before they reach any regulated dispensing channel.
Visibility did not equal ranking power for illegal vendors
Illegal links were less likely to hold the top position and were less common in the top 10 search results in countries that permit online sales of over-the-counter and prescription medicines than in countries that prohibit online sales. Search engine redirection affected 56.6% of illegal vendor links, a finding that suggests a substantial portion of the illicit marketplace is not static or transparent. Web addresses can redirect users, obscure destination pages, and complicate attempts to map the real route from query to vendor.
One sentence captures the risk with unusual force: search visibility alone can determine which medicine seller a patient sees first.
Across the dataset, legitimate online pharmacies still outnumbered illegal vendors and generally outranked them. Yet the presence of illegal results across so many jurisdictions means the problem is not confined to a few weak-regulation countries or to a narrow set of products. Exposure was broad, and it persisted even where legal pharmacy access online was established.
Regulatory permissiveness changed the search result mix
Countries that permitted online sales of over-the-counter and prescription-only medicines had fewer illegal vendor links in the top 10 than countries that prohibited online sales. That pattern matters because it points to a regulatory pressure valve: when legitimate online supply is clearer and more accessible, illegal vendors appear to lose some of the search engine space they would otherwise occupy. In other words, the absence of a lawful digital channel may push consumer demand into less safe corners of the web.
The study also shows that regulatory control is not the only force shaping exposure. Search engine algorithms, commercial optimization, and country-specific enforcement all interact. A patient searching for a common product such as amoxicillin may be less vulnerable than someone searching for a controlled substance, but the risk does not disappear. A regulated product can still be met with a fraudulent site, and a lawful market can still be undercut by an illegal one.
Why the exposure pattern matters clinically
The clinical danger of illegal online medicine sales is not abstract. Substandard or falsified products can fail to treat infection, expose patients to toxic impurities, or deliver unpredictable doses. For antimicrobials, that failure can prolong illness and contribute to avoidable resistance pressure. For sedatives and other controlled medicines, uncontrolled potency and unsupervised access raise the stakes for overdose, dependence, withdrawal, and dangerous drug interactions.
Online access is meant to improve convenience and reach, especially for people who face mobility barriers, travel distance, or limited local pharmacy access. The same convenience becomes hazardous when search engines surface illegitimate vendors alongside licensed pharmacies, because patients often cannot distinguish a compliant pharmacy from a counterfeit seller by appearance alone. The study’s results therefore sit at the intersection of digital health, pharmacy regulation, and consumer protection.
Search engine governance now belongs in drug-safety policy
The findings point to a shared responsibility between regulators and search engine providers. Harmonised action across European countries would help, but national rules alone are unlikely to be enough if search platforms continue to surface illegal vendors prominently in some settings. Better enforcement against illicit pharmacy domains, stronger verification signals for licensed sellers, and active suppression of fraudulent listings would all reduce the odds that a patient lands on a dangerous site first.
Search engines already function as front doors to care information and medicine access. When those front doors are not aligned with pharmacy law, the result is a digital version of unsafe dispensing. The evidence here supports tighter coordination between public authorities and platform operators, especially for controlled substances and in countries where legal online sales remain restricted.
The study leaves one clear operational problem on the table: search exposure is measurable, but the downstream impact on actual purchasing behavior was not captured. That leaves the key clinical and policy question open—how many users who encounter illegal vendors in search results go on to buy from them, and how often does that exposure translate into harm?